Drugs / CP-316,311
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00143091 | Apr 2005 → Apr 2006 | major depressive disorder | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP-316,311 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00143091 ↗ |
| Action | Inhibit | “CP-316,311, a selective nonpeptide antagonist of corticotropin-releasing hormone type 1 (CRH(1)) receptors” PMID 18413705 ↗ Apr 2008 |
| Modality | Small molecule | “CP-316,311, a selective nonpeptide antagonist of corticotropin-releasing hormone type 1 (CRH(1)) receptors” PMID 18413705 ↗ Apr 2008 |